Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crescent Biopharma Inc (CBIO)

Crescent Biopharma Inc (CBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,470
  • Shares Outstanding, K 13,893
  • Annual Sales, $ 794 K
  • Annual Income, $ -37,880 K
  • EBIT $ -57 M
  • EBITDA $ -57 M
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.33

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 51.11%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 0.00% on 12/02/25
  • IV Low 0.00% on 12/02/25
  • Expected Move (DTE 14) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,820
  • Open Int (30-Day) 2,802
  • Expected Range 13.21 to 13.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.16
  • Number of Estimates 4
  • High Estimate -1.04
  • Low Estimate -1.31
  • Prior Year -11.00
  • Growth Rate Est. (year over year) +89.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.30 +1.54%
on 12/05/25
16.35 -23.61%
on 12/04/25
+0.06 (+0.48%)
since 11/05/25
3-Month
9.81 +27.32%
on 10/14/25
16.35 -23.61%
on 12/04/25
-1.75 (-12.29%)
since 09/05/25
52-Week
9.81 +27.32%
on 10/14/25
37.00 -66.24%
on 02/18/25
-16.06 (-56.25%)
since 12/05/24

Most Recent Stories

More News
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data...

CBIO : 12.48 (-3.93%)
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to ...

CBIO : 12.48 (-3.93%)
Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave...

CBIO : 12.48 (-3.93%)
Crescent Biopharma: Q3 Earnings Snapshot

Crescent Biopharma: Q3 Earnings Snapshot

CBIO : 12.48 (-3.93%)
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors  Advancing ADCs in the...

CBIO : 12.48 (-3.93%)
Crescent Biopharma to Present at November Investor Conferences

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave...

CBIO : 12.48 (-3.93%)
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity  IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients...

CBIO : 12.48 (-3.93%)
Crescent Biopharma to Present at September Investor Conferences

WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave...

CBIO : 12.48 (-3.93%)
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring...

CBIO : 12.48 (-3.93%)
Crescent Biopharma: Q2 Earnings Snapshot

Crescent Biopharma: Q2 Earnings Snapshot

CBIO : 12.48 (-3.93%)

Business Summary

Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. Crescent Biopharma, formerly known as GlycoMimetics Inc., is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 19.43
2nd Resistance Point 17.89
1st Resistance Point 15.44
Last Price 12.48
1st Support Level 11.45
2nd Support Level 9.91
3rd Support Level 7.46

See More

52-Week High 37.00
Fibonacci 61.8% 26.61
Fibonacci 50% 23.41
Fibonacci 38.2% 20.20
Last Price 12.48
52-Week Low 9.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar